<DOC>
	<DOCNO>NCT00507494</DOCNO>
	<brief_summary>The purpose study test whether pioglitazone able prevent progression diabetic nephropathy kidney transplant recipient diabetes mellitus .</brief_summary>
	<brief_title>Influence Pioglitazone Renal Transplant Function Diabetics</brief_title>
	<detailed_description>About 30 % kidney transplant recipient develop diabetes mellitus . This condition risk factor graft dysfunction , graft loss increase mortality patient . Inflammatory reaction within graft proteinuria consider pathogenetic mechanism . Recent study indicate pioglitazone might beneficial effect urinary protein excretion type 2 diabetic patient diabetic nephropathy able reduce systemic inflammation . This lead hypothesis pioglitazone could improve proteinuria kidney transplant patient diabetes . Comparison : Effects pioglitazone vs. placebo proteinuria renal function kidney transplant recipient cross study .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>kidney transplantation ( &gt; 6 month ago ) ; stable graft function diabetes mellitus type 2 acceptable glycemia ( HbA1c &lt; 8 % ) creatinin clearance ( MDRD ) &gt; 30 ml/min 1,73mÂ² ) proteinuria &gt; 30 mg/24 hr type 1 diabetes pregnant breast feed woman congestive heart failure ( &gt; stage 1 NYHA ) creep creatinin treatment rejection within 3 month prior inclusion ALT , AST &gt; 2.5 fold upper limit normal uncontrolled hypertension hypo hyperthyroidism</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>posttransplant diabetes mellitus</keyword>
	<keyword>kidney transplantation</keyword>
	<keyword>filtration fraction</keyword>
	<keyword>proteinuria</keyword>
</DOC>